Sapient Capital LLC Purchases New Shares in Charles River Laboratories International, Inc. (NYSE:CRL)

Sapient Capital LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,533 shares of the medical research company's stock, valued at approximately $835,000.

Several other large investors also recently modified their holdings of the company. VisionPoint Advisory Group LLC grew its stake in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC bought a new position in Charles River Laboratories International in the third quarter worth approximately $37,000. Operose Advisors LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth $42,000. Venturi Wealth Management LLC lifted its position in Charles River Laboratories International by 74.7% during the third quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after purchasing an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group purchased a new stake in Charles River Laboratories International in the third quarter worth about $57,000. Institutional investors own 98.91% of the company's stock.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now directly owns 13,550 shares of the company's stock, valued at approximately $3,437,635. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now owns 2,596 shares of the company's stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock valued at $3,693,663 in the last ninety days. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

CRL traded up $3.58 during trading hours on Friday, hitting $233.47. The company's stock had a trading volume of 466,193 shares, compared to its average volume of 482,082. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The business's 50-day moving average price is $252.23 and its 200-day moving average price is $224.20. The stock has a market cap of $12.03 billion, a price-to-earnings ratio of 25.35, a P/E/G ratio of 1.83 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $991.25 million. During the same period in the previous year, the firm posted $2.98 EPS. The business's quarterly revenue was down 7.9% on a year-over-year basis. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CRL. Argus lifted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a "buy" rating in a report on Monday, March 18th. Robert W. Baird raised their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the company an "outperform" rating in a report on Thursday, February 15th. Guggenheim lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. lifted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. Finally, Citigroup upped their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a "neutral" rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.23.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).